Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
about
Bioflavonoids as poisons of human topoisomerase II alpha and II betaIdentification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transportersReversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell linemAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.Tumour heterogeneity and the evolution of polyclonal drug resistanceCharacterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutationThe necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells.A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent.Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspotAltered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cellsMechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNAAnalysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiaeDetection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies.Antineoplastic drug resistance and breast cancer.Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.The role of DNA topoisomerases II in drug resistance.Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches.Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaksChemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.Topoisomerase II and the response to antileukemic therapy.A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.
P2860
Q24627367-F53C5AB7-A22C-467A-99EE-206693FA7521Q24648348-55F86B5F-8E7E-4C16-95AB-A4EAAD511EC5Q24800442-0F489284-6166-44C1-B504-76AA991FE25EQ25255833-8FE8A692-191E-4BEE-83BB-EBEB41EDCF39Q26866803-F2EBAA5C-069B-49D5-A84F-DC918AB467A1Q28507775-87FD4F39-0355-4FE2-8138-2B45CFEEC070Q33442825-C04664D9-1E20-413C-9581-1E8C547C783BQ33940540-C1D04AFC-1216-4182-A397-02CE6329B274Q35221459-8E3020A9-0491-410A-A954-463FBBCA8899Q35978105-58E66210-6B81-4FDF-BB1F-971DFB7886A2Q36080575-156DBA5E-5D31-45A1-9E04-EFDC31FCCAF1Q36135162-7DCDA170-0FD6-4A29-A0A5-C80D865D6D6BQ36135236-FF504DBF-9A48-4C23-8AF8-823651CE768BQ36231995-30B87BAA-7E5A-40BC-B4FA-4046F23C5FA7Q38356131-58AA5D40-6D78-475A-AFED-0E6DE86F8BCBQ38475694-69DA8E7C-4DC1-430E-9E18-22670FF2F23EQ40619705-60E5873B-21C5-4B35-A1A0-ECFD9A444F48Q40630446-A23EA89E-01D8-44D4-9DCE-919265F0BF94Q40800678-43A21053-3B46-4D15-8219-55E44B837FA6Q40876344-C9C3B285-E72D-44B7-A079-9FD6E82E7252Q41147596-716051AD-DE92-450E-9D69-24D9136F9051Q41202524-5E91EA4C-AEE7-4E06-9864-578C7FC564E0Q41391609-6FAF1DA7-FAF1-41C8-A67B-185B21361358Q41571202-E07D83E4-9FB0-4991-82D6-8A5B99B2F1D1Q42114704-63F8922D-CDCA-438C-A30C-74961C7428E6Q47957249-7E6FE1E9-5E70-43D0-A41F-CCF848C20E8DQ53796376-57A131E9-3BA1-4FB1-8918-9C2890AD8FF6Q54120146-8CC6401C-4725-4CF5-97CD-33F932DF8113Q54182306-C6842098-07F1-4829-9204-8936F4533096Q54959930-86E43E07-95A3-4FDE-A1D3-B9720F43275F
P2860
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Expression of a mutant DNA top ...... for resistance to teniposide.
@en
Expression of a mutant DNA top ...... for resistance to teniposide.
@nl
type
label
Expression of a mutant DNA top ...... for resistance to teniposide.
@en
Expression of a mutant DNA top ...... for resistance to teniposide.
@nl
prefLabel
Expression of a mutant DNA top ...... for resistance to teniposide.
@en
Expression of a mutant DNA top ...... for resistance to teniposide.
@nl
P2093
P2860
P356
P1476
Expression of a mutant DNA top ...... for resistance to teniposide.
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.17.7654
P407
P577
1991-09-01T00:00:00Z